Vega NCT, Vega GLG, Marín D

Language: Spanish
References: 13
Page: 265-268
PDF size: 183.06 Kb.

ABSTRACT

Adalimumab (Humira^®) is a monoclonal antibody, humanized with approved use for the management of severe chronic psoriasis with a relatively good safety profile, however it may present an increased risk of the presence of more severe infections, development of neoplasms as well as the reactivation of latent infections.
The case of a 64-year-old patient with a diagnosis of psoriasis in management with adalimumab (Humira^®) with adequate response of the dermatosis for which he came to our service was presented, however presenting as a complication the presentation of a squamous cell carcinoma of the penis with the history of a previous hpv infection having a fatal outcome.

REFERENCES

1. Raval G y Mehta P, tnf-α inhibitors: are they carcinogenic?, Drug, Healthcare and Patient Safety 2010; 2:241-7.

2. European Medicines Agency, Humira pre-filled pen, pre-filled syringe and vial: summary of product characteristics, 2015. Disponible en: http://www.ema.europa.eu. Consultado: 15 de octubre de 2015.

3. Kreuter A, Occurrence of penile intraepithelial neoplasia following adalimumab treatment for psoriatic arthritis, Archives of Dermatology 2011; 147(8):1001.

4. Gallegos-Bolaños J et al., High prevalence of co-infection between human papillomavirus (hpv) 51 and 52 in Mexican population, bmc Cancer 2017; 17:531.

5. Daling JR, Madeleine MM, Johnson LG et al., Penile cancer: importance of circumcision, human papillomavirus and smoking in in situ and invasive disease, Int J Cancer 2005; 116:606-16.

6. Gregory J y Giuliano AR, The role of human papilloma virus in penile carcinogenesis and preneoplastic lesions a potential target for vaccination and treatment strategies, Urol Clin N Am 2016; 43:419-25.

7. Clark PE, Spiess PE, Agarwal N, Biagioli MC et al., Penile cancer: Clinical Practice Guidelines in Oncology, J Natl Compr Canc Netw 2013; 11(5):594-615.

8. Gisondi P, Altomare G, Ayala F, Bardazzi F et al., Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis, J Eur Acad Dermatol Venereol 2017; 31(5):774-90.

9. Ingles DJ, Pierce Campbell CM, Messina J, Stoler M et al., Human papillomavirus virus (hpv) genotype-and age-specific analyses of external genital lesions among men in the hpv infection in men (him) study, J infect Dis 2015; 2011(7):1060-7.

10. Kyo S, Inoue M, Hayasaka N et al., Regulation of early gene expression of human papillomavirus type 16 by inflammatory cytokines, Virology 1994; 200(1):130-9.

11. Leonardi C, Papp K, Strober B, Reich K et al., The long-term safety of adalimumab treatment in moderate to severe psoriasis, Am J Clin Dermatol 2011; 12(5):321-37.

12. Burmeste GR, Panaccione R, Gordon KB, McIlraith MJ y Lacerda AP, Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease, Ann Rheum Dis 2013; 72:517-24.

13. Hansen BT, Orumaa M, Lie AK et al., Trends incidence, mortality and survival of penile squamous cell carcinoma in Norway 1956-2015, Int J Cancer 2018; 142:1586-93.